Table 2.
Anti MRSA agents | Type | Limitation |
---|---|---|
Vancomycin | Glycopeptide | A progressive increase in minimum inhibitory concentration (MIC) Variability in tissue penetration due to its strong protein binding property In order to achieve clinical effectiveness, (AUC/MIC ratio of 400), maintaining high trough levels is nephrotoxic |
Daptomycin | Lipopeptide | Ineffective in patients suffering from pneumonia because of being rendered inactive when coming in contact with pulmonary surfactant Prone to decrease in susceptibility with increase in MIC of Vancomycin |
Tigecycline | Glycylcycline | Increased risk of mortality Ineffective in HA-MRSA or patients with pneumonia Low serum levels due to high protein binding |
Linezolid | Oxazolidinone | Causes bone marrow suppression, lactic acidosis and peripheral and optic neuropathy |